

=> file medline hcaplus biosis biotechds embase
COST IN U.S. DOLLARS SINCE FILE TOTAL
FULL ESTIMATED COST ENTRY SESSION

FILE 'MEDLINE' ENTERED AT 13:21:42 ON 04 FEB 2005

FILE 'HCAPLUS' ENTERED AT 13:21:42 ON 04 FEB 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 13:21:42 ON 04 FEB 2005
Copyright (c) 2005 The Thomson Corporation.

FILE 'BIOTECHDS' ENTERED AT 13:21:42 ON 04 FEB 2005
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'EMBASE' ENTERED AT 13:21:42 ON 04 FEB 2005
COPYRIGHT (C) 2005 Elsevier Inc. All rights reserved.

```

=> s AP-dextran conjugate
L1           1 AP-DEXTRAN CONJUGATE

=> d 11

L1  ANSWER 1 OF 1  HCPLUS  COPYRIGHT 2005 ACS on STN
AN 2004:133978  HCPLUS
DN 140:177309
TI Tissue non-specific alkaline phosphatase conjugate with dextran and its
use as standard for quantitative AP assay
IN Schneidinger, Bernd; Meier, Thomas; Schmuck, Rainer; Xiao, Ji-Xing
PA F. Hoffmann-La Roche Aktiengesellschaft, Switz.
SO Jpn. Kokai Tokkyo Koho, 14 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

      PATENT NO.          KIND     DATE      APPLICATION NO.      DATE
      -----          -----    -----      -----          -----
PI   JP 2004049240        A2    20040219      JP 2003-276312    20030717
      CA 2433479         AA    20040122      CA 2003-2433479   20030716
      EP 1405907         A2    20040407      EP 2003-16363    20030719
      EP 1405907         A3    20041013
      R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
          IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
      US 2004082027        A1    20040429      US 2003-624154    20030721
PRAI EP 2002-162444        A    20020722

```

=> s alkaline phosphatase and dextran
L2 469 ALKALINE PHOSPHATASE AND DEXTRAN

=> s alkaline phosphatase and dextran conjugate?
L3 9 ALKALINE PHOSPHATASE AND DEXTRAN CONJUGATE?

```
=> dup rem 13
PROCESSING COMPLETED FOR L3
L4          6 DUP REM L3 (3 DUPLICATES REMOVED)
```

```
=> dup rem 12  
PROCESSING COMPLETED FOR L2  
L5          280 DUP REM L2 (189 DUPLICATES REMOVED)
```

-> d 14 1-6 ihib ab

L4 ANSWER 1 OF 6 HCAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 2004:902115 HCAPLUS
 DOCUMENT NUMBER: 141:384388
 TITLE: Morpholino imaging and therapy via amplification targeting
 INVENTOR(S): Hnatowich, Donald J.; He, Jiang; Liu, Guozheng; Gupta, Suresh; Zhang, Yumin; Rusckowski, Mary
 PATENT ASSIGNEE(S): Immunomedics, Inc., USA
 SOURCE: PCT Int. Appl., 40 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004091525	A2	20041028	WO 2004-US11517	20040415
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: US 2003-462692P P 20030415
 AB The present invention provides a kit and a method for targeting of a diagnostic or therapeutic agent to a target site in a mammal having a pathol. condition. The kit comprises, in sep. containers, (A) a first conjugate comprising a targeting moiety and a morpholino oligomer (MORF), wherein said targeting moiety selectively binds to a primary, target-specific binding site of the target site or to a substance produced by or assocd. with the target site; (B) optionally, a clearing agent; (C) a second conjugate comprising multiple copies of complementary morpholino oligomer (cMORF) and a diagnostic agent or therapeutic agent; wherein the cMORF is bound to a polymer; and (D) a third conjugate comprising a MORF and a radiolabel. The method for targeting of a diagnostic or therapeutic agent comprises administering (A), optionally (B), (C) and (D) to a mammal. For example, whole body images obtained simultaneously of three nude mice each bearing LS174T tumors were presented. The first animal received MORF-99mTc (3 h before imaging), the second one received MORF-99mTc and the cMORF-polymer (21 h before imaging), while the study animal (amplification) received the MORF-99mTc, cMORF-polymer, and the anti-CEA antibody (MN14)-MORF (51 h before imaging). The images show tumor only in the study animals receiving both the antibody and the polymer, providing evidence that in vivo amplification targeting is feasible and has been achieved.

L4 ANSWER 2 OF 6 HCAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 2004:133978 HCAPLUS
 DOCUMENT NUMBER: 140:177309
 TITLE: Tissue non-specific alkaline phosphatase conjugate with dextran and its use as standard for quantitative AP assay
 INVENTOR(S): Schneidinger, Bernd; Meier, Thomas; Schmuck, Rainer; Xiao, Ji-Xing
 PATENT ASSIGNEE(S): F. Hoffmann-La Roche Aktiengesellschaft, Switz.
 SOURCE: Jpn. Kokai Tokkyo Koho, 14 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2004049240	A2	20040219	JP 2003-276312	20030717
CA 2433479	AA	20040122	CA 2003-2433479	20030716
EP 1405907	A2	20040407	EP 2003-16363	20030719
EP 1405907	A3	20041013		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 2004082027	A1	20040429	US 2003-624154	20030721
PRIORITY APPLN. INFO.:			EP 2002-16244	A 20020722

AB Dextran conjugate of tissue non-specific alk.
phosphatase (tns-AP) obtained by reacting nonglycosylated tns-AP and
activated dextran in aq. soln., and use of the AP-dextran
conjugate as std. for quant. AP assay, are disclosed.
Nonglycosylated tns-AP can be obtained by expressing tns-AP in
prokaryotes. Expression of human tns-AP in E. coli, and conjugation with
dextran T-40 (av. mol. wt. 40 kDa) are described. After dextran
conjugation, the activity of tns-AP was 70 ~ 90% of the non-conjugated
tns-AP.

L4 ANSWER 3 OF 6 HCPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 1

ACCESSION NUMBER: 2003:777993 HCPLUS

DOCUMENT NUMBER: 139:287262

TITLE: PNA probes derived from ribosomal DNA for the
diagnostic detection of *Bacillus anthracis*

INVENTOR(S): Stender, Henrik; Hyldig-Nielsen, Jens J.

PATENT ASSIGNEE(S): Boston Probes, Inc., USA

SOURCE: PCT Int. Appl., 40 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003080857	A2	20031002	WO 2003-US8890	20030321
WO 2003080857	A3	20040408		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003232402	A1	20031218	US 2003-393855	20030321
EP 1487858	A2	20041222	EP 2003-723808	20030321
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
PRIORITY APPLN. INFO.:			US 2002-366424P	P 20020321
			WO 2003-US8890	W 20030321

AB Peptide nucleic acid probes derived from ribosomal DNA are described for
the detn. of *Bacillus anthracis*. Specificity of the probes for *B.*
anthracis in fluorescent in situ hybridization is demonstrated.

L4 ANSWER 4 OF 6 HCPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1999:784342 HCPLUS

DOCUMENT NUMBER: 132:10507

TITLE: Modified DELISA immunoassay for the detection of autoantibodies and other analytes
 INVENTOR(S): Mehta, Harshvardhan B.; Kurn, Nurith
 PATENT ASSIGNEE(S): Dade Behring Inc., USA
 SOURCE: PCT Int. Appl., 63 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9963345 A1		19991209	WO 1999-US11446	19990524

W: JP

RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE
 PRIORITY APPLN. INFO.: US 1998-87839 19980529

AB The invention relates to methods of detg. the presence or amt. of an analyte in a sample suspected of contg. the analyte, said method comprising the steps of: (a) bringing together in an aq. medium to form a mixt.: (i) the sample; (ii) at least one specific binder for the analyte; (iii) a first binding agent coupled to either (1) exogenous analyte or (2) the specific binder for the analyte; (iv) a support comprising a second binding agent; (b) adding an activator to the mixt., wherein the activator binds the first binding agent and the second binding agent of the support to immobilize the first binding agent; (c) detg. the amt. of the analyte in the sample by detecting the immobilized first binding agent, the presence or amt. thereof being related to the presence or amt. of the analyte in the sample. The invention also relates to a modified DELISA assay in which the analyte is an antibody/autoantibody; the binding mol. is an antigen to the antibody, the first binding agent is coupled to exogenous antigen. Thus anti GAD (glutamic acid decarboxylase) autoantibody was detd. in the sera of IDDM (insulin dependent diabetes mellitus) patients using a one plate assay. Biotinylated BSA was immobilized to Nunc U8 maxisorp microtiterplate; biotinylated GAD soln. was incubated with the sample on the plate; thereafter protein A reagent was added, followed by incubation and the addn. of a streptavidin reagent. Finally the plate was rinsed; monoclonal antibody-HRP conjugate was added; after incubation, tetra-Me benzidine and hydrogen peroxidase were added; the intensity was measured at 630 nm in a plate reader.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 6 HCPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 1993:120484 HCPLUS
 DOCUMENT NUMBER: 118:120484
 TITLE: Water-soluble, polymer-based reagents and conjugates comprising moieties derived from divinyl sulfone
 INVENTOR(S): Lihme, Allan Otto Fog; Boenisch, Thomas
 PATENT ASSIGNEE(S): Immunodex K/S, Den.
 SOURCE: PCT Int. Appl., 149 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9301498	A1	19930121	WO 1992-DK206	19920629
W: AU, CA, CS, FI, HU, JP, KP, KR, NO, PL, RO, RU				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, MC, NL, SE				
US 5543332	A	19960806	US 1991-789757	19911108
CA 2112992	AA	19930121	CA 1992-2112992	19920629
CA 2112992	C	20020611		
AU 9223489	A1	19930211	AU 1992-23489	19920629

AU 667051	B2	19960307		
EP 594772	A1	19940504	EP 1992-916161	19920629
EP 594772	B1	19960828		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, MC, NL, SE				
AT 142021	E	19960915	AT 1992-916161	19920629
ES 2094920	T3	19970201	ES 1992-916161	19920629
JP 3340434	B2	20021105	JP 1993-501899	19920629
NO 9400030	A	19940303	NO 1994-30	19940104
PRIORITY APPLN. INFO.:				
		DK 1991-1309	A 19910704	
		US 1991-789757	A 19911108	
		WO 1992-DK206	A 19920629	

AB Water-sol. reagents and conjugates which are particularly well suited for use, for example, in biol. relevant detection, quantification, and targetting procedures, e.g. in immunohistochem., antibody immobilization, sepn., or purifn., DNA hybridization tests, and flow cytometry, are based on a polymeric carrier to which are covalently attached .gtoreq.1 moieties derived from divinyl sulfone, each of which moieties is attached to the carrier via a covalent linkage formed between one of the 2 vinyl groups of a divinyl sulfone and a reactive functionality on the polymeric carrier. The mol. species, of which .gtoreq.1 may be attached to a carrier mol., is an antigen, antibody, hapten, gene probe, hormone, enzyme, drug, dye, fluorophore, etc. Methods are provided for the prepn. of the reagents and conjugates. High-mol.-wt. dextran was activated by reaction with divinyl sulfone and then coupled with horseradish peroxidase and with straptavidin. The conjugate was complexed with biotinylated rabbit anti-human .kappa. light chain. The complex was tested in an ELISA and in an immunohistochem. procedure.

L4 ANSWER 6 OF 6 MEDLINE on STN DUPLICATE 2
 ACCESSION NUMBER: 94086252 MEDLINE
 DOCUMENT NUMBER: PubMed ID: 7505268
 TITLE: Phase I clinical and pharmacokinetic trial of dextran conjugated doxorubicin (AD-70, DOX-OXD).
 AUTHOR: Danhauser-Riedl S; Hausmann E; Schick H D; Bender R; Dietzfelbinger H; Rastetter J; Hanauske A R
 CORPORATE SOURCE: Department of Medicine I, Technische Universitat Munchen, Germany.
 SOURCE: Investigational new drugs, (1993 May-Aug) 11 (2-3) 187-95.
 Journal code: 8309330. ISSN: 0167-6997.

PUB. COUNTRY: United States
 DOCUMENT TYPE: (CLINICAL TRIAL)
 (CLINICAL TRIAL, PHASE I)
 Journal; Article; (JOURNAL ARTICLE)
 LANGUAGE: English
 FILE SEGMENT: Priority Journals
 ENTRY MONTH: 199401
 ENTRY DATE: Entered STN: 19940209
 Last Updated on STN: 19960129
 Entered Medline: 19940124

AB Coupling of anthracyclines to high-molecular-weight carriers may alter drug disposition and improve antitumor effects. We have performed a clinical phase I trial of doxorubicin coupled to dextran (70000 m.w.). The drug was administered as single dose i.v. every 21-28 days. Thirteen patients have received a total of 24 courses (median 2; range 1-3). At the starting dose of 40 mg/m² doxorubicin equivalent (DOXeq), WHO grade IV thrombocytopenia was noted in 2/2 patients. WHO grade IV hepatotoxicity and WHO grade III cardiotoxicity were noted in a patient with preexisting heart disease. Five patients were treated with 12.5 mg/m² DOXeq. Maximal toxicity at this dose level was WHO grade III thrombocytopenia and local phlebitis (WHO grade II) in 1/5 patients, elevation of alkaline phosphatase (WHO grade III) and WHO grade III vomiting in another patient. Subsequently, five patients received 20 mg/m² DOXeq. Hepatotoxicity was noted in 5/5 patients (1 x WHO grade IV, 1 x WHO grade III). Thrombocytopenia was noted in 3/5 patients (1 x WHO grade IV, 2 x

WHO grade III). At 12.5 mg/m² DOXeq, a patient diagnosed with a malignant fibrous histiocytoma had stable disease for 4 months. Pharmacokinetic analyses of total and free doxorubicin were performed in plasma and urine. The maximum peak plasma concentration (ppc) for total DOX was 12.3 micrograms/ml at 40 mg/m² DOXeq. The area under the plasma concentration time curve (AUC) ranged from 28.83-80.21 micrograms/ml*h with dose-dependent elimination half lives (t_{1/2} alpha: 0.02-0.87 h; t_{1/2} beta: 2.69-11.58 h; t_{1/2} gamma: 41.44-136.58 h). (ABSTRACT TRUNCATED AT 250 WORDS)

=> d his

(FILE 'HOME' ENTERED AT 13:21:11 ON 04 FEB 2005)

FILE 'MEDLINE, HCPLUS, BIOSIS, BIOTECHDS, EMBASE' ENTERED AT 13:21:42 ON
04 FEB 2005

L1 1 S AP-DEXTRAN CONJUGATE
L2 469 S ALKALINE PHOSPHATASE AND DEXTRAN
L3 9 S ALKALINE PHOSPHATASE AND DEXTRAN CONJUGATE?
L4 6 DUP REM L3 (3 DUPLICATES REMOVED)
L5 280 DUP REM L2 (189 DUPLICATES REMOVED)

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	23.54	23.75
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-3.65	-3.65

STN INTERNATIONAL LOGOFF AT 13:25:42 ON 04 FEB 2005